Lipocine

LPCN NASDAQ
1.580
-0.200
-11.24%
Pre Market: 1.700 +0.12 +7.59% 09:03 05/22 EDT
Open
1.770
Prev Close
1.780
High
1.789
Low
1.550
Volume
1.00K
Avg Vol (3M)
339.70K
52 Week High
2.640
52 Week Low
1.040
% Turnover
0.00%
Market Cap
34.09M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers Lipocine LPCN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
MORE >

Recently

Name
Price
%Change